The Phase I trial of 90Y-DOTA-anti-CD25 basiliximab, in combination with fludarabine, melphalan, and total marrow and lymphoid irradiation (TMLI), aims to enhance outcomes for patients with high-risk acute leukemia or myelodysplastic syndrome. Given the high unmet need in this patient population, successful results could position the asset favorably in the hematologic malignancy treatment landscape. The collaboration with the National Cancer Institute (NCI) may enhance credibility and facilitate future funding opportunities. However, the competitive landscape includes established therapies and emerging agents targeting similar pathways, necessitating a robust differentiation strategy. The trial's focus on a specific patient demographic (age ≥ 60 years or younger with comorbidities) may limit market size but could also streamline regulatory pathways if successful.